Kornimate/medical-research-clean huggingface dataset:
smoking cessation support for patients with rheumatologic diseases via whatsapp

Conditions: Tobacco Use Cessation

Summary: smoking cessation support for patients with rheumatologist diseases is an underestimated issue. in the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. therefore to increase the willingness to quit as well as to increase the access to evidence based tobacco cessation support using new comminication technologies can be relevant. investigators' aim in this study is to examine the effect of including whatsapp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the rheumatology outpatient clinic.

in this randomized controlled study, the sample will be randomly divided to 2 arms. in one arm, usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. in the other arm, the intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via whatsapp. primary outcome measures will be the quit rate of both arms at 3rd, 6th and 12th month. secondary outcomes will be access to evidence based smoking cessation support, admission rate of smoking cessation clinic and treatment use duration of cessation medications.

Eligibility criteria:
inclusion criteria: 1. patients applying to the rheumatology outpatient clinic 2. those aged 18 and over 3. those who are active smokers 4. those diagnosed with inflammatory rheumatic disease 5. those who gave informed written consent to participate in the study exclusion criteria: 1. those with active psychiatric disease diagnoses such as psychosis, major depression, schizophrenia among their current diagnoses 2. those with cognitive dysfunction

Keywords: tobacco cessation rheumatologic diseases smoking cessation support
a multicenter study evaluating azr-md-001 in patients with meibomian gland dysfunction and evaporative dry eye disease (ded)

Conditions: Meibomian Gland Dysfunction; Dry Eye

Summary: az201801 is a multicenter study of azr-md-001 ointment and azr-md-001 vehicle in patients with meibomian gland dysfunction (mgd) and evaporative dry eye disease (ded)

az201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and tolerability of azr-md-001 ointment and azr-md-001 vehicle in patients with meibomian gland dysfunction (mgd) and evaporative dry eye disease (ded)

Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older * best-corrected visual acuity (bcva) of 20/40 or better (snellen equivalent), using the logarithm of the minimum angle of resolution (logmar) in each eye * evidence of meibomian gland obstruction * reported dry eye signs and symptoms within the past 3 months exclusion criteria: * uncontrolled ocular disease (except for mgd and dry eye disease/keratoconjunctivitis sicca) or uncontrolled systemic disease * glaucoma, ocular hypertension, or intraocular pressure (iop) in either eye at screening ≥24 mm hg or has planned insertion/removal of glaucoma filtration shunts/devices during the study * corneal abnormality or disorder that impacts normal spreading of the tear film or corneal integrity * bcva worse than 20/40 in either eye * current use of punctal plugs, anticipated insertion during the study, or a history of punctal cautery in either eye
repeatability and reproducibility of lens zonule length measurement using arcscan insight 100

Conditions: Zonule of Zinn Abnormality; Zonular Cataract

Summary: the purpose of this study is to evaluate the intra-examiner repeatability and inter-examiner reproducibility in lens zonule length measurements using very high-frequency (vhf) digital ultrasound (arcscan insight 100).


Eligibility criteria:
inclusion criteria: * subjects with no ocular disease except ametropia * subjects will be able to understand and willing to sign an informed consent exclusion criteria: * previous ocular surgery * subjects not being able to tolerate or not willing to use pilocarpine eye drops * subjects has active ocular infection or inflammation * subjects not being able to look steadily * subjects not being able to open eyes wide in sterile saline even after topical anesthesia
different peep settings of covid-19 induced ards

Conditions: COVID-19; Mechanical Ventilation Pressure High; Acute Respiratory Distress Syndrome

Summary: this was a multi-center prospective study. all consecutive severe cases of covid-19 whose po2/fio2\<300mmhg with invasive ventilation admitted to 5 fixed-point receive covid-19 patients hospitals in wuhan from 5 march to 15 march 2020 were included. epidemiological, clinical data, lung mechanics, artery blood gas test and hemodynamics at three methods to titrate peep, optimizing oxygenation, optimizing compliance, ardsnet. the study was approved by the ethics committee of zhongda hsopital, southeast university.

after peep titration, peep settings could be set by optimizing oxygenation, optimizing compliance, ardsnet.

Eligibility criteria:
inclusion criteria: * covid-19 patients with mechanical ventilation * po2/fio2\<300mmhg * ages\>18 years exclusion criteria: * pneumothorax * pregnant * hemodynamics is unstable

Keywords: ards covid-19 mechanical ventilation peep
the influence of siscom on intracranial electrode implantation in epilepsy surgical candidates

Conditions: Epilepsy

Summary: the aim of this study is to determine the role of siscom (see below) in aiding clinicians to manage epilepsy surgery candidates. siscom is already a routine component of pre-surgical epilepsy evaluation at mayo clinic. in particular, we are interested in assessing whether use of siscom can minimize the need for prolonged (\>24 hours) invasive monitoring with electrodes placed on the surface of the brain prior to surgical resection. note: this study has recruited the required number of patients and is closed to further enrolment.

successful epilepsy surgery depends on accurate identification of the area of brain from which seizures originate (the epileptogenic zone). there are many non-invasive tests (including eeg and mri) to indicate this area. some patients require implantation of intracranial electrodes in order to determine the epileptogenic zone. a test known as siscom (subtraction ictal-interictal spect co-registered with mri) has been validated as a non-invasive means of indicating the epileptogenic zone. however, this test is not widely available in the us, and it is not known how often the additional information provided by siscom makes a difference to clinical decision-making. in order to determine the contribution of siscom towards clinical decision-making in epilepsy surgery candidates, we will ask epileptologists at mayo clinic to consider case presentations given all clinical information except for siscom results, and then to reconsider those same cases in conjunction with siscom data. this will indicate the degree to which siscom influences decision making. 50 patients at mayo clinic (38 adults, 12 children) will be enrolled.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of localization-related epilepsy * evaluated by clinical epileptologist at mayo clinic * siscom ordered by treating physician * case presented at weekly epilepsy surgery conference * patient consent

Keywords: clinical decision-making ictal spect epilepsy surgery
the effect of lidocaine patch for postoperative pain

Conditions: Acute Pain

Summary: the lidocaine patch is currently only permitted for post herpetic neuralgia but the investigators want to study its effectiveness in post operative pain after inguinal herniorrhaphy

after open unilateral inguinal herniorrhaphy, patients are randomly divided into group l and group p groups. group l attaches two lidocaine patches for 12 hours, above and below the incision site. group p attaches two placebo patches for 12 hours, above and below the incision site. pain scores are recorded for 30 minutes, 2 hours, 24 hours, and 1 week after surgery.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status i - ii * scheduled open unilateral herniorrhaphy exclusion criteria: * body mass index (bmi) \< 18.5 or ≥ 35 kg/m2 * severe renal or hepatic dysfunction * allergy to amide-based local anesthetic agents * taking class 1 antiarrhythmic drugs (tocainide and mexiletine, etc.)
pain assessment via force measurement using eegg after blockade of the lumbar facet joints

Conditions: Pain Measurement

Summary: the emotion egg, or "eegg" for short, is a sample series of a device for testing a new pain measurement method that is not yet on the market. the aim is to investigate whether the trial device and the eegg method (eegg plus software) are suitable for supporting, improving or even replacing the communication between doctor and patient, which still takes place via the numerical rating scale (nrs) and the pain diary. issues of acceptability in comparison to the pain diary and the nrs are to be considered. measurements should be recorded in real time; no orientation to the previous value is possible for the patient.


Eligibility criteria:
inclusion criteria: * elective interventional blockade of lumbar facet joints due to lumbar facet osteoarthritis * chronic pain (\>3 months, most severe pain on motion in the last three months ≥3 (nrs)) * age ≥18 years * legal capacity * proficiency in the german language * presence of a written informed consent from the patient * inpatient pain patient exclusion criteria: * participation in other interventional trials * individuals who have a dependent/employee relationship with the sponsor or investigator * cognitive impairment that could affect the use of the eegg * impaired fist closure and/or reduction of gross strength in the hand area * mono- or poly-neuropathy in the hand area * allergy to plastics

Keywords: pain measurement blockade of the lumbar facet joints peri-interventional grip strenth chronic pain
correlation between fractional exhaled nitric oxide (feno) levels and asthma exacerbation

Conditions: Bronchial Asthma

Summary: the purpose of this study is to determine mean or median of fractional exhaled nitric oxide (feno) in thai atopic asthmatic children that divided into subgroups due to asthma exacerbation according to the global initiative for asthma guideline.

from many previous studies, fractional exhaled nitric oxide (feno) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients. in thailand, this field of study is less extend, especially in children population. the investigators hypothesized that patients with asthma exacerbation may have high level of fractional exhaled nitric oxide (feno) than non exacerbation group. it is therefore desirable to examine the association between fractional exhaled nitric oxide (feno) and asthma exacerbation among atopic asthmatic thai children and will be the main objective of this research.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of atopic bronchial asthma follow up in clinic of allergy and clinical immunology, siriraj hospital exclusion criteria: * smoker or past history of smoking * chronic disease eg. hiv infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, copd, bronchiectasis * drink ethanol within 48 hours before enrollment * history of upper or lower respiratory tract infection within 6 weeks before enrollment drink caffeine within day before enrollment during pregnancy history of systemic steroid use within 8 weeks before enrollment

Keywords: bronchial asthma fractional exhaled nitric oxide (feno) asthma exacerbation
efficacy of herbal galactogogues in breastfeeding mothers

Conditions: Weight Gain

Summary: herbal teas with galactogoge effects have been used extensively in recent years in order to increase the amount of breast milk in lactating mothers. we also investigated whether a sleep-induced herbal tea (still-tee; mamsel®) was effective in regulating the sleep of these mothers. plain water was used as placebo.

herbal teas with galactogoge effects have been used extensively in recent years in order to increase the amount of breast milk in lactating mothers. mothers of premature babies often have problems in breastfeeding and this study was designed to investigate if such herbal teas has any effect on the increasing of breast milk in mothers of premature babies. we also investigated whether a sleep-induced herbal tea (still-tee; mamsel®) was effective in regulating the sleep of these mothers. plain water was used as placebo.

Eligibility criteria:
inclusion criteria: * babies with gestational age of 35-42 weeks * breasfed babies * lactating mothers * babies admitted to outpatient clinics of neonatology within the the first week of life exclusion criteria: * babies with gestational age of \<35 weeks * not breast feeding mothers * babies admitted to outpatient clinics of neonatology within the the first week of life
efficacy and safety of pz01 treatment in patients with r/r cd19+ b-cell acute lymphoblastic leukemia/b cell lymphoma

Conditions: B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma

Summary: the major aim of this research is to assess the feasibility, safety and effectiveness of cd19 car-t cell therapy for relapsed/ refractory acute lymphoblastic leukemia/ b cell lymphoma patients who have applied it.


Eligibility criteria:
inclusion criteria: 1. subjects or their legal guardians participate in this experiment voluntarily and informed consent form must be signed 2. in accordance with national comprehensive cancer network (nccn) all guidelines for patients (2016, v.1) and cd19+b-all/b cell lymphoma patients diagnosed by histology 3. in accordance with r/r cd19+ b-all/b cell lymphoma diagnosis, including any of the following situations: 1. getting through 2 treatments of standard chemotherapy with cr not yet obtained 2. reach cr for the first inducement, but cr lasts for ≦12 months 3. r/r cd19+ b-all/b cell lymphoma for no positive effect after first or repeated remedial treatment 4. ≧2 times of recurrence 4. remedial chemotherapy is not used within 4 weeks before cell therapy 5. immunosuppressive drug is not used within 4 weeks before cell therapy, including but not limited to systemic hormone therapy 6. antibody drug treatment is not received within 2 weeks before cell therapy 7. normal cardiac motion shown by echocardiography, left ventricular ejection fraction (lvef) ≥50%, with no pericardial effusion and severe symptoms of cardiac arrhythmia 8. no pulmonary active infection is found, with normal pulmonary function and indoor air sao2 ≧92% 9. no contraindications for leukapheresis 10. expected survival \>3 months 11. grade 0 or 1 of ecog performance status exclusion criteria: 1. pregnant and breastfeeding women 2. uncontrolled active infection 3. uncontrolled infectious disease is diagnosed, such as hiv, syphilis, hepatitis a, hepatitis b, hepatitis c and e. 4. patients who have used a large amount of glucocorticoid or other immunosuppressive drugs within 4 weeks 5. stage ii-iv acute/chronic general graft versus host disease 6. gene therapy has been undergone in the past
bms-582664 in combination with erbitux in patients with advanced gastrointestinal malignancies

Conditions: Colorectal Cancer

Summary: this is a phase i dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of bms-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.


Eligibility criteria:
inclusion criteria: * diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy * feeling well other than cancer diagnosis (ie lab work, no infection, etc) * available tumor tissue sample from prior surgery * measurable disease on scans * 4-6 weeks since prior therapy and recovered from the effects of prior therapy * men and women, ages 18 and above * women must not be pregnant or breastfeeding

Keywords: advanced gastrointestinal malignancies
feasibility and safety of total percutaneous closure of femoral arterial access sites in the veno-arterial ecmo patients

Conditions: Cardiogenic Shock; Extracorporeal Membrane Oxygenation; Myocarditis; Hypertension, Pulmonary; Pulmonary Embolism; Heart Arrest; Medication Overdoses

Summary: the most frequent access site for veno-arterial extracorporeal membrane oxygenation (va-ecmo) is the common femoral artery (cfa), using either an open or percutaneous technique. currently, percutaneous closure devices for femoral arterial access sites are approved for use only when a 10-f or smaller sheath has been used. however, the availability of the perclose proglide (abbott laboratories, chicago, il) device has now made it possible to perform percutaneous vessel closure after using larger sheaths.the preclose technique using perclose proglide, has been widely used in endovascular procedures. in a prospective randomized study, complication rates at the access site were similar in patients who underwent total percutaneous access (including percutaneous arteriotomy closure) than in those who underwent surgical cutdown and subsequent surgical closure. total percutaneous closure of femoral arterial access sites increases patient comfort and decreases the rate of wound infections and lymphatic fistulas.\[6,7\] furthermore, patients are mobilized and discharged earlier following the use of closure devices than with compression alone. despite the above observations, no data have been published regarding percutaneous closure of femoral artery access sites in patients who have undergone va-ecmo. in this study, we evaluated the safety and feasibility of a percutaneous closure technique using perclose proglide to close the cfa access site after va-ecmo.


Eligibility criteria:
inclusion criteria: - the study included all patients who underwent va-ecmo and in whom perclose proglide was deployed to achieve hemostasis during closure of the cfa site. exclusion criteria: * patients were excluded if 24 hour and 30-day follow-up data regarding the access sites and other clinical outcomes were not available.

Keywords: decannulation veno-arterial extracorporeal membrane oxygenation proglide vascular complications
feasibility of passive data collection in dementia subjects with agitation

Conditions: Dementia; Alzheimer Disease; Vascular Dementia; Frontotemporal Dementia; Lewy Body Dementia; Mixed Dementia

Summary: this is a multi-center, observational, feasibility study, to evaluate long term passive data collection, data quality, and user experience of healthmode agitation (apps) to collect motion, location, physiological, and audio data; and ecoa and ema responses with mobile devices (iphone, apple watch). the purpose of this study is to evaluate and improve healthmode apps data collection and usability in subjects experiencing agitation in the context of dementia.


Eligibility criteria:
inclusion criteria: * male and female subjects 18 years and older. * subjects who have met dsm-5 criteria for dementia (all cause) * subjects with a recent history of agitation in the past 6 months to a point that impairs social activities, requires staffing or medical intervention (kick, bite, flailing, etc.), impairs ability for functional activities of daily living, as disclosed by a caregiver or documented in the medical record. * subjects resident in a group home, nursing home, or assisted living are eligible to participate. * subjects who can read, understand and provide written informed consent or who have a legally acceptable representative (lar) * subjects who are willing and able to carry a smartphone and wear an activity tracker on their wrist or hand, alone or with the help of a caregiver. * subjects who, either alone or with a caregiver, are able to operate a smartphone and wrist or hand-worn activity tracker, alone or with the help of a caregiver. * subjects who are in good general health prior to study participation as determined by a detailed medical history, and in the opinion of the principal investigator. * subjects, who are able to ambulate without an assistive device, or with a single point cane. exclusion criteria: * subjects who are unwilling or unable to carry a smartphone and wear an activity tracker on their wrist or hand. * subjects with serious or unstable medical illnesses. these include current hepatic (moderate-severe hepatic impairment), renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease, congestive heart failure), endocrinologic, neurologic or hematologic disease. * subjects who are considered by the investigator, for any reason, to be an unsuitable candidate.